{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T16:42:44Z","timestamp":1782146564776,"version":"3.54.5"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T00:00:00Z","timestamp":1662249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["NWA.1160.18.300"],"award-info":[{"award-number":["NWA.1160.18.300"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Opioids are effective in pain-management, but long-term opioid users can develop prescription opioid use disorder (OUD). One treatment strategy in patients with OUD is rotating from a short-acting opioid to a long-acting opioid (buprenorphine\/naloxone (BuNa) or methadone). Both BuNa and methadone have been shown to be effective strategies in patients with OUD reducing opioid misuse, however data on head-to-head comparison in patients with chronic non-malignant pain and prescription OUD are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This two-armed open-label, randomized controlled trial aims to compare effectiveness between BuNa and methadone in patients with chronic non-malignant with prescription OUD (n\u2009=\u2009100). Participants receive inpatient rotation to either BuNa or methadone with a flexible dosing regimen. The primary outcome is opioid misuse 2 months after rotation. Secondary outcomes include treatment compliance, side effects, analgesia, opioid craving, quality of life, mood symptoms, cognitive and physical functioning over 2- and 6 months follow-up. Linear mixed model analysis will be used to evaluate change in outcome parameters over time between the treatment arms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is one of the first studies comparing buprenorphine\/naloxone and methadone for treating prescription OUD in a broad patient group with chronic non-malignant pain. Results may guide future treatment for patients with chronic pain and prescription OUD.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/\">https:\/\/www.trialregister.nl\/<\/jats:ext-link>, NL9781<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-022-00326-1","type":"journal-article","created":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T03:16:30Z","timestamp":1662261390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Buprenorphine\/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9471-6779","authenticated-orcid":false,"given":"Hannah","family":"Ellerbroek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra A. S.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Kramers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnt F. A.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,4]]},"reference":[{"issue":"5","key":"326_CR1","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1213\/ANE.0000000000002500","volume":"125","author":"JC Ballantyne","year":"2017","unstructured":"Ballantyne JC. Opioids for the treatment of chronic pain: mistakes made, lessons learned, and future directions. Anesth Analg. 2017;125(5):1769\u201378.","journal-title":"Anesth Analg"},{"issue":"4","key":"326_CR2","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1097\/j.pain.0000000000002423","volume":"163","author":"E Nury","year":"2022","unstructured":"Nury E, Schmucker C, Nagavci B, Motschall E, Nitschke K, Schulte E, et al. Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: a systematic review and meta-analyses. Pain. 2022;163(4):610\u201336.","journal-title":"Pain"},{"issue":"6","key":"326_CR3","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1213\/01.ANE.0000152191.29311.9B","volume":"100","author":"C Buntin-Mushock","year":"2005","unstructured":"Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP. Age-dependent opioid escalation in chronic pain patients. Anesth Analg. 2005;100(6):1740\u20135.","journal-title":"Anesth Analg"},{"issue":"4","key":"326_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","volume":"156","author":"KE Vowles","year":"2015","unstructured":"Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569\u201376.","journal-title":"Pain"},{"issue":"1","key":"326_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ejp.970","volume":"21","author":"T O'Brien","year":"2017","unstructured":"O\u2019Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, et al. European pain federation position paper on appropriate opioid use in chronic pain management. Eur J Pain. 2017;21(1):3\u201319.","journal-title":"Eur J Pain"},{"key":"326_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ypmed.2015.04.003","volume":"80","author":"WM Compton","year":"2015","unstructured":"Compton WM, Boyle M, Wargo E. Prescription opioid abuse: problems and responses. Prev Med. 2015;80:5\u20139.","journal-title":"Prev Med"},{"issue":"6","key":"326_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/M19-1488","volume":"171","author":"R Chou","year":"2019","unstructured":"Chou R, Ballantyne J, Lembke A. Rethinking opioid dose tapering, prescription opioid dependence, and indications for buprenorphine. Ann Intern Med. 2019;171(6):427\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"326_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63\u201375.","journal-title":"Harv Rev Psychiatry"},{"key":"326_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","volume":"161","author":"G Kourounis","year":"2016","unstructured":"Kourounis G, Richards BD, Kyprianou E, Symeonidou E, Malliori MM, Samartzis L. Opioid substitution therapy: lowering the treatment thresholds. Drug Alcohol Depend. 2016;161:1\u20138.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"326_CR10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1056\/NEJMra1604339","volume":"375","author":"MA Schuckit","year":"2016","unstructured":"Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357\u201368.","journal-title":"N Engl J Med"},{"issue":"2","key":"326_CR11","first-page":"Cd002207","volume":"6","author":"RP Mattick","year":"2014","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;6(2):Cd002207.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"326_CR12","first-page":"1048","volume":"289","author":"AM Davis","year":"1999","unstructured":"Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-d-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999;289(2):1048\u201353.","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"326_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2165\/00003495-200969050-00006","volume":"69","author":"JS Orman","year":"2009","unstructured":"Orman JS, Keating GM. Buprenorphine\/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577\u2013607.","journal-title":"Drugs"},{"issue":"4","key":"326_CR14","doi-asserted-by":"publisher","first-page":"137","DOI":"10.18773\/austprescr.2017.043","volume":"40","author":"ME Jauncey","year":"2017","unstructured":"Jauncey ME, Nielsen S. Community use of naloxone for opioid overdose. Aust Prescr. 2017;40(4):137\u201340.","journal-title":"Aust Prescr"},{"issue":"3","key":"326_CR15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/15360288.2011.589490","volume":"25","author":"C Ramasubbu","year":"2011","unstructured":"Ramasubbu C, Gupta A. Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother. 2011;25(3):219\u201330.","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"10","key":"326_CR16","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40263-019-00660-0","volume":"33","author":"S Mercadante","year":"2019","unstructured":"Mercadante S, Arcuri E, Santoni A. Opioid-induced tolerance and hyperalgesia. CNS Drugs. 2019;33(10):943\u201355.","journal-title":"CNS Drugs"},{"issue":"6","key":"326_CR17","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1089\/jpm.2012.0612","volume":"16","author":"SR Salpeter","year":"2013","unstructured":"Salpeter SR, Buckley JS, Bruera E. The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med. 2013;16(6):616\u201322.","journal-title":"J Palliat Med"},{"issue":"1\u20132","key":"326_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.pain.2005.06.030","volume":"118","author":"W Koppert","year":"2005","unstructured":"Koppert W, Ihmsen H, K\u00f6rber N, Wehrfritz A, Sittl R, Schmelz M, et al. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain. 2005;118(1\u20132):15\u201322.","journal-title":"Pain"},{"issue":"12","key":"326_CR19","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s40265-018-0953-z","volume":"78","author":"MP Davis","year":"2018","unstructured":"Davis MP, Pasternak G, Behm B. Treating chronic pain: an overview of clinical studies centered on the buprenorphine option. Drugs. 2018;78(12):1211\u201328.","journal-title":"Drugs"},{"issue":"10","key":"326_CR20","doi-asserted-by":"publisher","first-page":"e0186315","DOI":"10.1371\/journal.pone.0186315","volume":"12","author":"P Lagisetty","year":"2017","unstructured":"Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: what actually works? A systematic review. PLoS ONE. 2017;12(10):e0186315.","journal-title":"PLoS ONE"},{"issue":"5","key":"326_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1017\/S146114570700836X","volume":"11","author":"M Soyka","year":"2008","unstructured":"Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11(5):641\u201353.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"326_CR22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/add.12333","volume":"109","author":"YI Hser","year":"2014","unstructured":"Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, et al. Treatment retention among patients randomized to buprenorphine\/naloxone compared to methadone in a multi-site trial. Addiction. 2014;109(1):79\u201387.","journal-title":"Addiction"},{"issue":"2","key":"326_CR23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1151\/spp04224","volume":"2","author":"HE Jones","year":"2004","unstructured":"Jones HE. Practical considerations for the clinical use of buprenorphine. Sci Pract Perspect. 2004;2(2):4\u201320.","journal-title":"Sci Pract Perspect"},{"issue":"1","key":"326_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.017","volume":"75","author":"G Gerra","year":"2004","unstructured":"Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, et al. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend. 2004;75(1):37\u201345.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"326_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","volume":"62","author":"S Petitjean","year":"2001","unstructured":"Petitjean S, Ladewig D, Stohler R, Waldvogel D, Deglon J-J, Livoti S, et al. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend. 2001;62(1):97\u2013104.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"326_CR26","first-page":"Cd011117","volume":"9","author":"S Nielsen","year":"2016","unstructured":"Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;9(5):Cd011117.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"326_CR27","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2146\/ajhp070392","volume":"66","author":"J Stringer","year":"2009","unstructured":"Stringer J, Welsh C, Tommasello A. Methadone-associated Q-T interval prolongation and torsades de pointes. Am J Health Syst Pharm. 2009;66(9):825\u201333.","journal-title":"Am J Health Syst Pharm"},{"issue":"9","key":"326_CR28","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1038\/npp.2016.38","volume":"41","author":"E Falcon","year":"2016","unstructured":"Falcon E, Browne CA, Leon RM, Fleites VC, Sweeney R, Kirby LG, et al. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology. 2016;41(9):2344\u201351.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"326_CR29","doi-asserted-by":"publisher","first-page":"e785","DOI":"10.4088\/JCP.13m08725","volume":"75","author":"JF Karp","year":"2014","unstructured":"Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785\u201393.","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"326_CR30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1017\/S0033291720000525","volume":"50","author":"CA Madison","year":"2020","unstructured":"Madison CA, Eitan S. Buprenorphine: prospective novel therapy for depression and PTSD. Psychol Med. 2020;50(6):881\u201393.","journal-title":"Psychol Med"},{"issue":"16","key":"326_CR31","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.3390\/jcm10163727","volume":"10","author":"AFA Schellekens","year":"2021","unstructured":"Schellekens AFA, Veldman SE, Suranto ESD, van Rijswijk SM, van der Wal SEI, Schene AH, et al. Beneficial effects of opioid rotation to buprenorphine\/naloxone on opioid misuse, craving, mental health, and pain control in chronic non-cancer pain patients with opioid use disorder. J Clin Med. 2021;10(16):3727.","journal-title":"J Clin Med"},{"key":"326_CR32","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/j.pain.0000000000002462","volume":"163","author":"S Veldman","year":"2021","unstructured":"Veldman S, van Beek M, van Rijswijk S, Ellerbroek H, Timmerman H, van der Wal S, et al. Effects of opioid rotation to buprenorphine\/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. Pain. 2021;163:955.","journal-title":"Pain"},{"issue":"1","key":"326_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1080\/10550887.2012.759872","volume":"32","author":"AM Neumann","year":"2013","unstructured":"Neumann AM, Blondell RD, Jaanim\u00e4gi U, Giambrone AK, Homish GG, Lozano JR, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68\u201378.","journal-title":"J Addict Dis"},{"issue":"1","key":"326_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/10550887.2019.1690929","volume":"38","author":"AM Neumann","year":"2020","unstructured":"Neumann AM, Blondell RD, Hoopsick RA, Homish GG. Randomized clinical trial comparing buprenorphine\/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. J Addict Dis. 2020;38(1):33\u201341.","journal-title":"J Addict Dis"},{"issue":"6","key":"326_CR35","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1177\/0269216311412415","volume":"26","author":"OMS Fredheim","year":"2011","unstructured":"Fredheim OMS, Moksnes K, Borchgrevink PC, Skurtveit S. Opioid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med. 2011;26(6):804\u201312.","journal-title":"Palliat Med"},{"issue":"12","key":"326_CR36","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/pme.12520","volume":"15","author":"D Daitch","year":"2014","unstructured":"Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr. Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014;15(12):2087\u201394.","journal-title":"Pain Med"},{"issue":"1\u20132","key":"326_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.drugalcdep.2012.08.002","volume":"128","author":"AJ Saxon","year":"2013","unstructured":"Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, et al. Buprenorphine\/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend. 2013;128(1\u20132):71\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"326_CR38","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1097\/j.pain.0000000000000160","volume":"156","author":"RD Treede","year":"2015","unstructured":"Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003\u20137.","journal-title":"Pain"},{"key":"326_CR39","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D. C: American Psychiatric Association; 2013.","edition":"5"},{"key":"326_CR40","unstructured":"Castor EDC. Castor Electronic Data Capture 2019 https:\/\/castoredc.com. Accessed 9 Dec 2021."},{"key":"326_CR41","unstructured":"de Jong CAJ, van Hoek AFM, Jongerhuis M, Fiers M, Ghijsen LCJL, Gottmer PBLM, et al. Richtlijn detox. 2004."},{"issue":"5","key":"326_CR42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1526-4637.2008.00461.x","volume":"9","author":"DJ Weschules","year":"2008","unstructured":"Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med. 2008;9(5):595\u2013612.","journal-title":"Pain Med"},{"issue":"4","key":"326_CR43","doi-asserted-by":"publisher","first-page":"19541","DOI":"10.3402\/jchimp.v2i4.19541","volume":"2","author":"E Wong","year":"2012","unstructured":"Wong E, Walker KA. A review of common methods to convert morphine to methadone. J Community Hosp Intern Med Perspect. 2012;2(4):19541.","journal-title":"J Community Hosp Intern Med Perspect."},{"key":"326_CR44","unstructured":"Dijkstra B, van Oort M, Schellekens A, de Haan H, De Jong CA. Richtlijn Detoxificatie van psychoactieve middelen: Verantwoord ambulant of intramuraal detoxificeren: Stichting Resultaten Scoren, Amersfoort; 2017."},{"key":"326_CR45","unstructured":"Zorginstituut Nederland. Methadon https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/m\/methadon. Accessed 23 Nov 2021."},{"key":"326_CR46","unstructured":"van den Brink W, van de Glind G, Schippers GM. Multidisciplinaire richtlijn opiaatverslaving: Nederlandse Vereniging voor Psychiatrie en Centrale Commissie Behandeling Hero\u00efneverslaafden; 2013."},{"issue":"1\u20132","key":"326_CR47","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.pain.2004.12.010","volume":"114","author":"D Bouhassira","year":"2005","unstructured":"Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1\u20132):29\u201336.","journal-title":"Pain"},{"issue":"11","key":"326_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0187961","volume":"12","author":"H Timmerman","year":"2017","unstructured":"Timmerman H, Steegers MAH, Huygen F, Goeman JJ, van Dasselaar NT, Schenkels MJ, et al. Investigating the validity of the DN4 in a consecutive population of patients with chronic pain. PLoS ONE. 2017;12(11): e0187961.","journal-title":"PLoS ONE"},{"key":"326_CR49","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.msksp.2017.05.010","volume":"30","author":"R Epping","year":"2017","unstructured":"Epping R, Verhagen AP, Hoebink EA, Rooker S, Scholten-Peeters GGM. The diagnostic accuracy and test-retest reliability of the Dutch PainDETECT and the DN4 screening tools for neuropathic pain in patients with suspected cervical or lumbar radiculopathy. Musculoskelet Sci Pract. 2017;30:72\u20139.","journal-title":"Musculoskelet Sci Pract"},{"issue":"6","key":"326_CR50","first-page":"393","volume":"49","author":"IM van Vliet","year":"2007","unstructured":"van Vliet IM, de Beurs E. The MINI-International Neuropsychiatric Interview. A brief structured diagnostic psychiatric interview for DSM-IV en ICD-10 psychiatric disorders. Tijdschrift Voor Psychiatrie. 2007;49(6):393\u20137.","journal-title":"Tijdschrift Voor Psychiatrie"},{"issue":"10","key":"326_CR51","first-page":"693","volume":"60","author":"ME Zandee","year":"2018","unstructured":"Zandee ME, de Jong K. The inter-rater reliability of the MINI-Plus. Tijdschr Psychiatr. 2018;60(10):693\u20138.","journal-title":"Tijdschr Psychiatr"},{"issue":"5","key":"326_CR52","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0924-9338(97)83297-X","volume":"12","author":"DV Sheehan","year":"1997","unstructured":"Sheehan DV, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Keskiner A, et al. The validity of the mini international neuropsychiatric interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry. 1997;12(5):232\u201341.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"326_CR53","first-page":"15","volume":"22","author":"B Schmand","year":"1991","unstructured":"Schmand B, Bakker D, Saan R, Louman J. The Dutch reading test for adults: a measure of premorbid intelligence level. Tijdschr Gerontol Geriatr. 1991;22(1):15\u20139.","journal-title":"Tijdschr Gerontol Geriatr"},{"issue":"8","key":"326_CR54","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3390\/jcm8081188","volume":"8","author":"M Garbusow","year":"2019","unstructured":"Garbusow M, Nebe S, Sommer C, Kuitunen-Paul S, Sebold M, Schad DJ, et al. Pavlovian-to-instrumental transfer and alcohol consumption in young male social drinkers: behavioral, neural and polygenic correlates. J Clin Med. 2019;8(8):1188.","journal-title":"J Clin Med"},{"key":"326_CR55","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.neubiorev.2016.09.020","volume":"71","author":"E Cartoni","year":"2016","unstructured":"Cartoni E, Balleine B, Baldassarre G. Appetitive pavlovian-instrumental transfer: a review. Neurosci Biobehav Rev. 2016;71:829\u201348.","journal-title":"Neurosci Biobehav Rev"},{"issue":"9","key":"326_CR56","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/AJP.0b013e3181f195ba","volume":"26","author":"SF Butler","year":"2010","unstructured":"Butler SF, Budman SH, Fanciullo GJ, Jamison RN. Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. Clin J Pain. 2010;26(9):770\u20136.","journal-title":"Clin J Pain"},{"issue":"1","key":"326_CR57","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/sjpain-2018-0012","volume":"18","author":"ISK Thong","year":"2018","unstructured":"Thong ISK, Jensen MP, Mir\u00f3 J, Tan G. The validity of pain intensity measures: what do the NRS, VAS, VRS, and FPS-R measure? Scand J Pain. 2018;18(1):99\u2013107.","journal-title":"Scand J Pain"},{"issue":"2","key":"326_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jpain.2003.12.005","volume":"5","author":"G Tan","year":"2004","unstructured":"Tan G, Jensen MP, Thornby JI, Shanti BF. Validation of the brief pain inventory for chronic nonmalignant pain. J Pain. 2004;5(2):133\u20137.","journal-title":"J Pain"},{"issue":"4","key":"326_CR59","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1533-2500.2011.00493.x","volume":"12","author":"TG Mayer","year":"2012","unstructured":"Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, et al. The development and psychometric validation of the central sensitization inventory. Pain Pract. 2012;12(4):276\u201385.","journal-title":"Pain Pract"},{"issue":"7","key":"326_CR60","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1097\/AJP.0000000000000306","volume":"32","author":"J Kregel","year":"2016","unstructured":"Kregel J, Vuijk PJ, Descheemaeker F, Keizer D, van der Noord R, Nijs J, et al. The Dutch central sensitization inventory (csi): factor analysis, discriminative power, and test-retest reliability. Clin J Pain. 2016;32(7):624\u201330.","journal-title":"Clin J Pain"},{"issue":"3","key":"326_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.pain.2010.11.013","volume":"152","author":"C Geber","year":"2011","unstructured":"Geber C, Klein T, Azad S, Birklein F, Gierthm\u00fchlen J, Huge V, et al. Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German research network on neuropathic pain (DFNS): a multi-centre study. Pain. 2011;152(3):548\u201356.","journal-title":"Pain"},{"issue":"3","key":"326_CR62","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","volume":"28","author":"The WHOQOL Group","year":"1998","unstructured":"The WHOQOL Group. Development of the world health organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551\u20138.","journal-title":"Psychol Med"},{"issue":"1","key":"326_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s11136-004-0787-x","volume":"14","author":"FJ Trompenaars","year":"2005","unstructured":"Trompenaars FJ, Masthoff ED, Van Heck GL, Hodiamont PP, De Vries J. Content validity, construct validity, and reliability of the WHOQOL-Bref in a population of Dutch adult psychiatric outpatients. Qual Life Res. 2005;14(1):151\u201360.","journal-title":"Qual Life Res"},{"issue":"1","key":"326_CR64","first-page":"35","volume":"34","author":"E de Beurs","year":"2001","unstructured":"de Beurs E, Van Dyck R, Marquenie LA, Lange A, Blonk RWB. De DASS: Een vragenlijst voor het meten van depressie, angst en stress [The DASS: A questionnaire for the measurement of depression, anxiety, and stress.]. Gedragstherapie. 2001;34(1):35\u201353.","journal-title":"Gedragstherapie"},{"issue":"Pt 2","key":"326_CR65","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1348\/014466503321903544","volume":"42","author":"JR Crawford","year":"2003","unstructured":"Crawford JR, Henry JD. The depression anxiety stress scales (DASS): normative data and latent structure in a large non-clinical sample. Br J Clin Psychol. 2003;42(Pt 2):111\u201331.","journal-title":"Br J Clin Psychol"},{"issue":"7","key":"326_CR66","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.jclinepi.2009.09.009","volume":"63","author":"SJ Kamper","year":"2010","unstructured":"Kamper SJ, Ostelo RW, Knol DL, Maher CG, de Vet HC, Hancock MJ. Global perceived effect scales provided reliable assessments of health transition in people with musculoskeletal disorders, but ratings are strongly influenced by current status. J Clin Epidemiol. 2010;63(7):760-6.e1.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"326_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.2044-8260.1982.tb01421.x","volume":"21","author":"DE Broadbent","year":"1982","unstructured":"Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The cognitive failures questionnaire (CFQ) and its correlates. Br J Clin Psychol. 1982;21(1):1\u201316.","journal-title":"Br J Clin Psychol"},{"issue":"6","key":"326_CR68","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/0191-8869(96)00024-4","volume":"20","author":"H Merckelbach","year":"1996","unstructured":"Merckelbach H, Muris P, Nijman H, de Jong PJ. Self-reported cognitive failures and neurotic symptomatology. Personality Individ Differ. 1996;20(6):715\u201324.","journal-title":"Personality Individ Differ"},{"issue":"4","key":"326_CR69","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"326_CR70","first-page":"S157-S","volume":"7","author":"H Chertkow","year":"2011","unstructured":"Chertkow H, Nasreddine Z, Johns E, Phillips N, McHenry C. P1\u2013143: The montreal cognitive assessment (MoCA): validation of alternate forms and new recommendations for education corrections. Alzheimer\u2019s Dementia. 2011;7:S157-S.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"5","key":"326_CR71","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1037\/a0017260","volume":"17","author":"ML Copersino","year":"2009","unstructured":"Copersino ML, Fals-Stewart W, Fitzmaurice G, Schretlen DJ, Sokoloff J, Weiss RD. Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol. 2009;17(5):337\u201344.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"1","key":"326_CR72","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1080\/14659891.2018.1497102","volume":"24","author":"CJWH Bruijnen","year":"2019","unstructured":"Bruijnen CJWH, Jansen M, Dijkstra BAG, Walvoort SJW, Lugtmeijer S, Markus W, et al. The montreal cognitive assessment (MoCA) as a cognitive screen in addiction health care: a validation study for clinical practice. J Substance Use. 2019;24(1):47\u201354.","journal-title":"J Substance Use"},{"key":"326_CR73","unstructured":"Rey A. L\u2019examen clinique en psychologie. 1958."},{"key":"326_CR74","unstructured":"Saan R, Deelman B. De 15-woordentest A en B (een voorlopige handleiding). Groningen: Afdeling Neuropsychologie, AZG. 1986."},{"issue":"6","key":"326_CR75","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1037\/h0054651","volume":"18","author":"JR Stroop","year":"1935","unstructured":"Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol. 1935;18(6):643.","journal-title":"J Exp Psychol"},{"issue":"3","key":"326_CR76","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/arclin\/2.3.265","volume":"2","author":"MD Franzen","year":"1987","unstructured":"Franzen MD, Tishelman AC, Sharp BH, Friedman AG. An investigation of the test-retest reliability of the stroop colorword test across two intervals. Arch Clin Neuropsychol. 1987;2(3):265\u201372.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"326_CR77","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.acn.2005.07.006","volume":"21","author":"TN Tombaugh","year":"2006","unstructured":"Tombaugh TN. A comprehensive review of the paced auditory serial addition test (PASAT). Arch Clin Neuropsychol. 2006;21(1):53\u201376.","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"326_CR78","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1183\/09031936.00194909","volume":"37","author":"C Casanova","year":"2011","unstructured":"Casanova C, Celli BR, Barria P, Casas A, Cote C, de Torres JP, et al. The 6-min walk distance in healthy subjects: reference standards from seven countries. Eur Respir J. 2011;37(1):150\u20136.","journal-title":"Eur Respir J"},{"key":"326_CR79","doi-asserted-by":"crossref","unstructured":"Sciurba FC, Slivka WA, editors. Six-minute walk testing. Seminars in respiratory and critical care medicine; Copyright\u00a9 1998 by Thieme Medical Publishers, Inc. 1998.","DOI":"10.1055\/s-2007-1009415"},{"issue":"3","key":"326_CR80","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1213\/01.ANE.0000133143.60584.38","volume":"99","author":"JL Apfelbaum","year":"2004","unstructured":"Apfelbaum JL, Gan TJ, Zhao S, Hanna DB, Chen C. Reliability and validity of the perioperative opioid-related symptom distress scale. Anesth Analg. 2004;99(3):699\u2013709.","journal-title":"Anesth Analg"},{"issue":"4","key":"326_CR81","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3758\/BRM.41.4.1149","volume":"41","author":"F Faul","year":"2009","unstructured":"Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009;41(4):1149\u201360.","journal-title":"Behav Res Methods"},{"key":"326_CR82","unstructured":"Nederlandse Federatie van Universitair Medische Centra. Richtlijn Kwaliteitsborging Mensgebonden Onderzoek. 2020."},{"issue":"4 Pt 1","key":"326_CR83","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0013-7006(06)76190-5","volume":"32","author":"V Vazquez","year":"2006","unstructured":"Vazquez V, Gury C, Laqueille X. Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006;32(4 Pt 1):478\u201386.","journal-title":"Encephale"},{"issue":"6","key":"326_CR84","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","volume":"10","author":"MP Davis","year":"2012","unstructured":"Davis MP. Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain. J Support Oncol. 2012;10(6):209\u201319.","journal-title":"J Support Oncol"},{"issue":"6","key":"326_CR85","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CP, Bertolini A, Sternieri E. Methadone\u2013metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50(6):551\u20139.","journal-title":"Pharmacol Res"},{"issue":"9","key":"326_CR86","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","volume":"94","author":"G Fischer","year":"1999","unstructured":"Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, St\u00fchlinger G, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999;94(9):1337\u201347.","journal-title":"Addiction"},{"issue":"6","key":"326_CR87","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.bja.2018.09.019","volume":"122","author":"C Higgins","year":"2019","unstructured":"Higgins C, Smith BH, Matthews K. Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. Br J Anaesth. 2019;122(6):e114\u201326.","journal-title":"Br J Anaesth"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-022-00326-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-022-00326-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T04:13:21Z","timestamp":1662264801000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-022-00326-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,4]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1186\/s13722-022-00326-1","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,4]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the region medical ethical board; Medisch Ethische Toestingscomissie Oost-Nederland (NL77333.091.21 \/ 2021-10521). Written informed consent to participate will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}